Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus.

Martini A, Ravelli A, Avcin T, Beresford MW, Burgos-Vargas R, Cuttica R, Ilowite NT, Khubchandani R, Laxer RM, Lovell DJ, Petty RE, Wallace CA, Wulffraat NM, Pistorio A, Ruperto N; Pediatric Rheumatology International Trials Organization (PRINTO).

J Rheumatol. 2019 Feb;46(2):190-197. doi: 10.3899/jrheum.180168. Epub 2018 Oct 1.

2.

Interleukin-1 in monocyte activation phenotypes in systemic juvenile idiopathic arthritis: Observations from a clinical trial of rilonacept, an interleukin-1 inhibitor.

Zhang Y, Gupta S, Ilstad-Minnihan A, Ayyangar S, Hay AD, Pascual V, Ilowite NT, Macaubas C, Mellins ED.

Clin Immunol. 2018 Sep;194:9-18. doi: 10.1016/j.clim.2018.06.005. Epub 2018 Jun 19.

3.

IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis.

Arthur VL, Shuldiner E, Remmers EF, Hinks A, Grom AA, Foell D, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Ilowite NT, Mellins ED, Russo R, Len C, Oliveira S, Yeung RSM, Rosenberg AM, Wedderburn LR, Anton J, Haas JP, Rösen-Wolff A, Minden K, Szymanski AM; INCHARGE Consortium, Thomson W, Kastner DL, Woo P, Ombrello MJ.

Arthritis Rheumatol. 2018 Aug;70(8):1319-1330. doi: 10.1002/art.40498. Epub 2018 Jun 28.

4.

Delays to Care in Pediatric Lupus Patients: Data From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.

Rubinstein TB, Mowrey WB, Ilowite NT, Wahezi DM; Childhood Arthritis and Rheumatology Research Alliance INVESTIGATORS.

Arthritis Care Res (Hoboken). 2018 Mar;70(3):420-427. doi: 10.1002/acr.23285. Epub 2018 Feb 7.

5.

The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months.

Beukelman T, Kimura Y, Ilowite NT, Mieszkalski K, Natter MD, Burrell G, Best B, Jones J, Schanberg LE; CARRA Registry Investigators.

Pediatr Rheumatol Online J. 2017 Apr 17;15(1):30. doi: 10.1186/s12969-017-0160-6.

6.

Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications.

Ombrello MJ, Arthur VL, Remmers EF, Hinks A, Tachmazidou I, Grom AA, Foell D, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Ilowite NT, Mellins ED, Russo R, Len C, Hilario MO, Oliveira S, Yeung RS, Rosenberg AM, Wedderburn LR, Anton J, Haas JP, Rosen-Wolff A, Minden K, Tenbrock K, Demirkaya E, Cobb J, Baskin E, Signa S, Shuldiner E, Duerr RH, Achkar JP, Kamboh MI, Kaufman KM, Kottyan LC, Pinto D, Scherer SW, Alarcón-Riquelme ME, Docampo E, Estivill X, Gül A; British Society of Pediatric and Adolescent Rheumatology (BSPAR) Study Group, Inception Cohort of Newly Diagnosed Patients with Juvenile Idiopathic Arthritis (ICON-JIA) Study Group, Childhood Arthritis Prospective Study (CAPS) Group, Randomized Placebo Phase Study of Rilonacept in sJIA (RAPPORT) Investigators, Sparks-Childhood Arthritis Response to Medication Study (CHARMS) Group, Biologically Based Outcome Predictors in JIA (BBOP) Group, Langefeld CD, Thompson S, Zeggini E, Kastner DL, Woo P, Thomson W.

Ann Rheum Dis. 2017 May;76(5):906-913. doi: 10.1136/annrheumdis-2016-210324. Epub 2016 Dec 7.

7.

Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.

Orrock JE, Ilowite NT.

Expert Rev Clin Pharmacol. 2016 Aug;9(8):1015-24. doi: 10.1080/17512433.2016.1204910. Epub 2016 Jul 6. Review.

PMID:
27367267
8.

2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Ravelli A, Minoia F, Davì S, Horne A, Bovis F, Pistorio A, Aricò M, Avcin T, Behrens EM, De Benedetti F, Filipovic L, Grom AA, Henter JI, Ilowite NT, Jordan MB, Khubchandani R, Kitoh T, Lehmberg K, Lovell DJ, Miettunen P, Nichols KE, Ozen S, Pachlopnik Schmid J, Ramanan AV, Russo R, Schneider R, Sterba G, Uziel Y, Wallace C, Wouters C, Wulffraat N, Demirkaya E, Brunner HI, Martini A, Ruperto N, Cron RQ; Paediatric Rheumatology International Trials Organisation; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society.

Ann Rheum Dis. 2016 Mar;75(3):481-9. doi: 10.1136/annrheumdis-2015-208982.

PMID:
26865703
9.

Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.

Ravelli A, Minoia F, Davì S, Horne A, Bovis F, Pistorio A, Aricò M, Avcin T, Behrens EM, De Benedetti F, Filipovic A, Grom AA, Henter JI, Ilowite NT, Jordan MB, Khubchandani R, Kitoh T, Lehmberg K, Lovell DJ, Miettunen P, Nichols KE, Ozen S, Pachlopnik Schmid J, Ramanan AV, Russo R, Schneider R, Sterba G, Uziel Y, Wallace C, Wouters C, Wulffraat N, Demirkaya E, Brunner HI, Martini A, Ruperto N, Cron RQ.

RMD Open. 2016 Jan 19;2(1):e000161. doi: 10.1136/rmdopen-2015-000161. eCollection 2016.

10.

HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis.

Ombrello MJ, Remmers EF, Tachmazidou I, Grom A, Foell D, Haas JP, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Mellins ED, Ilowite NT, Russo R, Len C, Hilario MO, Oliveira S, Yeung RS, Rosenberg A, Wedderburn LR, Anton J, Schwarz T, Hinks A, Bilginer Y, Park J, Cobb J, Satorius CL, Han B, Baskin E, Signa S, Duerr RH, Achkar JP, Kamboh MI, Kaufman KM, Kottyan LC, Pinto D, Scherer SW, Alarcón-Riquelme ME, Docampo E, Estivill X, Gül A; British Society of Pediatric and Adolescent Rheumatology (BSPAR) Study Group; Childhood Arthritis Prospective Study (CAPS) Group; Randomized Placebo Phase Study of Rilonacept in sJIA (RAPPORT) Investigators; Sparks-Childhood Arthritis Response to Medication Study (CHARMS) Group; Biologically Based Outcome Predictors in JIA (BBOP) Group, de Bakker PI, Raychaudhuri S, Langefeld CD, Thompson S, Zeggini E, Thomson W, Kastner DL, Woo P; International Childhood Arthritis Genetics (INCHARGE) Consortium.

Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15970-5. doi: 10.1073/pnas.1520779112. Epub 2015 Nov 23.

11.

2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Ravelli A, Minoia F, Davì S, Horne A, Bovis F, Pistorio A, Aricò M, Avcin T, Behrens EM, De Benedetti F, Filipovic L, Grom AA, Henter JI, Ilowite NT, Jordan MB, Khubchandani R, Kitoh T, Lehmberg K, Lovell DJ, Miettunen P, Nichols KE, Ozen S, Pachlopnik Schmid J, Ramanan AV, Russo R, Schneider R, Sterba G, Uziel Y, Wallace C, Wouters C, Wulffraat N, Demirkaya E, Brunner HI, Martini A, Ruperto N, Cron RQ; Paediatric Rheumatology International Trials Organisation; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society.

Arthritis Rheumatol. 2016 Mar;68(3):566-76. doi: 10.1002/art.39332. Epub 2016 Feb 9.

12.

Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.

Grom AA, Ilowite NT, Pascual V, Brunner HI, Martini A, Lovell D, Ruperto N; Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group, Leon K, Lheritier K, Abrams K.

Arthritis Rheumatol. 2016 Jan;68(1):218-28. doi: 10.1002/art.39407.

13.

Novel treatment options for juvenile idiopathic arthritis.

Steigerwald KA, Ilowite NT.

Expert Rev Clin Pharmacol. 2015;8(5):559-73. doi: 10.1586/17512433.2015.1061428. Review.

PMID:
26294075
14.

Reply: To PMID 24839206.

Ilowite NT; RAPPORT Investigators.

Arthritis Rheumatol. 2015 Mar;67(3):858. doi: 10.1002/art.38991. No abstract available.

15.

Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance project.

Ringold S, Hendrickson A, Abramson L, Beukelman T, Blier PR, Bohnsack J, Chalom EC, Gewanter HL, Gottlieb B, Hollister R, Hsu J, Hudgins A, Ilowite NT, Klein-Gitelman M, Lindsley C, Lopez Benitez JM, Lovell DJ, Mason T, Milojevic D, Moorthy LN, Nanda K, Onel K, Prahalad S, Rabinovich CE, Ray L, Rouster-Stevens K, Ruth N, Shishov M, Spalding S, Syed R, Stoll M, Vehe RK, Weiss JE, White AJ, Wallace CA, Sobel RE.

Arthritis Care Res (Hoboken). 2015 Apr;67(4):529-37. doi: 10.1002/acr.22487.

16.

Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.

Davì S, Minoia F, Pistorio A, Horne A, Consolaro A, Rosina S, Bovis F, Cimaz R, Gamir ML, Ilowite NT, Kone-Paut I, Feitosa de Oliveira SK, McCurdy D, Silva CA, Sztajnbok F, Tsitsami E, Unsal E, Weiss JE, Wulffraat N, Abinun M, Aggarwal A, Apaz MT, Astigarraga I, Corona F, Cuttica R, D'Angelo G, Eisenstein EM, Hashad S, Lepore L, Mulaosmanovic V, Nielsen S, Prahalad S, Rigante D, Stanevicha V, Sterba G, Susic G, Takei S, Trauzeddel R, Zletni M, Ruperto N, Martini A, Cron RQ, Ravelli A; Paediatric Rheumatology International Trials Organisation, the Childhood Arthritis and Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group, and the Histiocyte Society.

Arthritis Rheumatol. 2014 Oct;66(10):2871-80. doi: 10.1002/art.38769.

17.

Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.

Ilowite NT, Prather K, Lokhnygina Y, Schanberg LE, Elder M, Milojevic D, Verbsky JW, Spalding SJ, Kimura Y, Imundo LF, Punaro MG, Sherry DD, Tarvin SE, Zemel LS, Birmingham JD, Gottlieb BS, Miller ML, O'Neil K, Ruth NM, Wallace CA, Singer NG, Sandborg CI.

Arthritis Rheumatol. 2014 Sep;66(9):2570-9. doi: 10.1002/art.38699.

18.

Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors.

Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeft AS, Szer IS, Ringold S, Brunner HI, Schanberg LE, Sundel RP, Milojevic DS, Punaro MG, Chira P, Gottlieb BS, Higgins GC, Ilowite NT, Kimura Y, Johnson A, Huang B, Lovell DJ; Childhood Arthritis and Rheumatology Research Alliance (CARRA).

J Rheumatol. 2014 Jun;41(6):1163-70. doi: 10.3899/jrheum.131503. Epub 2014 May 1.

PMID:
24786928
19.
20.

Using registries to identify adverse events in rheumatic diseases.

Lionetti G, Kimura Y, Schanberg LE, Beukelman T, Wallace CA, Ilowite NT, Winsor J, Fox K, Natter M, Sundy JS, Brodsky E, Curtis JR, Del Gaizo V, Iyasu S, Jahreis A, Meeker-O'Connell A, Mittleman BB, Murphy BM, Peterson ED, Raymond SC, Setoguchi S, Siegel JN, Sobel RE, Solomon D, Southwood TR, Vesely R, White PH, Wulffraat NM, Sandborg CI.

Pediatrics. 2013 Nov;132(5):e1384-94. doi: 10.1542/peds.2013-0755. Epub 2013 Oct 21. Review.

21.

2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.

Ringold S, Weiss PF, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Nigrovic PA, Robinson AB, Vehe RK; American Collge of Rheumatology.

Arthritis Rheum. 2013 Oct;65(10):2499-512. doi: 10.1002/art.38092. No abstract available.

22.

2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.

Ringold S, Weiss PF, Beukelman T, Dewitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Nigrovic PA, Robinson AB, Vehe RK; American College of Rheumatology.

Arthritis Care Res (Hoboken). 2013 Oct;65(10):1551-63. doi: 10.1002/acr.22087. Review. No abstract available.

23.

Ultrasound and cartilage thickness in juvenile idiopathic arthritis: new findings, new questions.

Janow G, Ilowite NT.

J Rheumatol. 2013 Sep;40(9):1466-8. doi: 10.3899/jrheum.130737. No abstract available.

PMID:
23996991
24.

Systemic juvenile idiopathic arthritis: a review.

Hay AD, Ilowite NT.

Pediatr Ann. 2012 Nov;41(11). doi: 10.3928/00904481-20121022-10. Review. No abstract available.

PMID:
23814932
25.

Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I.

Wahezi DM, Ilowite NT, Wu XX, Pelkmans L, Laat B, Schanberg LE, Rand JH; Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators.

Lupus. 2013 Jun;22(7):702-11. doi: 10.1177/0961203313490241. Epub 2013 May 20.

26.

Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives.

Wahezi DM, Ilowite NT.

Expert Opin Pharmacother. 2013 Jun;14(8):975-89. doi: 10.1517/14656566.2013.783569. Epub 2013 Mar 26. Review.

PMID:
23528005
27.

Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.

Ardoin SP, Schanberg LE, Sandborg CI, Barnhart HX, Evans GW, Yow E, Mieszkalski KL, Ilowite NT, Eberhard A, Imundo LF, Kimura Y, Levy D, von Scheven E, Silverman E, Bowyer SL, Punaro L, Singer NG, Sherry DD, McCurdy DK, Klein-Gitelman M, Wallace C, Silver RM, Wagner-Weiner L, Higgins GC, Brunner HI, Jung L, Soep JB, Reed AM, Thompson SD; APPLE investigators.

Ann Rheum Dis. 2014 Mar;73(3):557-66. doi: 10.1136/annrheumdis-2012-202315. Epub 2013 Feb 22.

28.

Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology.

Ilowite NT, Sandborg CI, Feldman BM, Grom A, Schanberg LE, Giannini EH, Wallace CA, Schneider R, Kenney K, Gottlieb B, Hashkes PJ, Imundo L, Kimura Y, Lang B, Miller M, Milojevic D, O'Neil KM, Punaro M, Ruth N, Singer NG, Vehe RK, Verbsky J, Woodward A, Zemel L.

Pediatr Rheumatol Online J. 2012 Aug 29;10(1):31. doi: 10.1186/1546-0096-10-31.

29.

An i2b2-based, generalizable, open source, self-scaling chronic disease registry.

Natter MD, Quan J, Ortiz DM, Bousvaros A, Ilowite NT, Inman CJ, Marsolo K, McMurry AJ, Sandborg CI, Schanberg LE, Wallace CA, Warren RW, Weber GM, Mandl KD.

J Am Med Inform Assoc. 2013 Jan 1;20(1):172-9. doi: 10.1136/amiajnl-2012-001042. Epub 2012 Jun 25.

30.

Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma.

Li SC, Torok KS, Pope E, Dedeoglu F, Hong S, Jacobe HT, Rabinovich CE, Laxer RM, Higgins GC, Ferguson PJ, Lasky A, Baszis K, Becker M, Campillo S, Cartwright V, Cidon M, Inman CJ, Jerath R, O'Neil KM, Vora S, Zeft A, Wallace CA, Ilowite NT, Fuhlbrigge RC; Childhood Arthritis and Rheumatology Research Alliance (CARRA) Localized Scleroderma Workgroup.

Arthritis Care Res (Hoboken). 2012 Aug;64(8):1175-85. doi: 10.1002/acr.21687.

31.

Pediatric rheumatic disease: Vaccination in pediatric rheumatic disease--risks and benefits.

Janow G, Ilowite NT.

Nat Rev Rheumatol. 2012 Feb 14;8(4):188-90. doi: 10.1038/nrrheum.2012.13. No abstract available.

PMID:
22331060
32.

Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis.

DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, Schneider R, Stoll ML, Angeles-Han S, Milojevic D, Schikler KN, Vehe RK, Weiss JE, Weiss P, Ilowite NT, Wallace CA; Juvenile Idiopathic Arthritis Disease-specific Research Committee of Childhood Arthritis Rheumatology and Research Alliance.

Arthritis Care Res (Hoboken). 2012 Jul;64(7):1001-10. doi: 10.1002/acr.21625.

33.

Giant coronary artery aneurysms in juvenile polyarteritis nodosa: a case report.

Canares TL, Wahezi DM, Farooqi KM, Pass RH, Ilowite NT.

Pediatr Rheumatol Online J. 2012 Jan 5;10(1):1. doi: 10.1186/1546-0096-10-1.

34.

Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis.

Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeft AS, Szer IS, Ringold S, Brunner HI, Schanberg LE, Sundel RP, Milojevic D, Punaro MG, Chira P, Gottlieb BS, Higgins GC, Ilowite NT, Kimura Y, Hamilton S, Johnson A, Huang B, Lovell DJ; Childhood Arthritis and Rheumatology Research Alliance.

Arthritis Rheum. 2012 Jun;64(6):2012-21. doi: 10.1002/art.34343. Epub 2011 Dec 19.

35.

Prevalence of annexin A5 resistance in children and adolescents with rheumatic diseases.

Wahezi DM, Ilowite NT, Rajpathak S, Rand JH.

J Rheumatol. 2012 Feb;39(2):382-8. doi: 10.3899/jrheum.110768. Epub 2011 Dec 15.

PMID:
22174207
36.

A dose schedule for intraarticular steroids in juvenile arthritis.

Eberhard BA, Ilowite NT, Sison C.

J Rheumatol. 2012 Feb;39(2):374-6. doi: 10.3899/jrheum.110125. Epub 2011 Dec 1.

PMID:
22133622
37.

Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference.

Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, Curran M, Feldman BM, Gewanter H, Griffin T, Haines K, Hoeltzel MF, Isgro J, Kahn P, Lang B, Lawler P, Shaham B, Schmeling H, Scuccimarri R, Shishov M, Stringer E, Wohrley J, Ilowite NT, Wallace C; Juvenile Dermatomyositis Subcommittee of the Childhood Arthritis and Rheumatology Research Alliance.

Arthritis Care Res (Hoboken). 2012 Apr;64(4):546-53. doi: 10.1002/acr.20695.

38.

Use of atorvastatin in systemic lupus erythematosus in children and adolescents.

Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, Mieszkalski KL, Ilowite NT, Eberhard A, Imundo LF, Kimura Y, von Scheven E, Silverman E, Bowyer SL, Punaro M, Singer NG, Sherry DD, McCurdy D, Klein-Gitelman M, Wallace C, Silver R, Wagner-Weiner L, Higgins GC, Brunner HI, Jung L, Soep JB, Reed AM, Provenzale J, Thompson SD; Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators.

Arthritis Rheum. 2012 Jan;64(1):285-96. doi: 10.1002/art.30645.

39.

Detection of active disease in juvenile idiopathic arthritis: sensitivity and specificity of the physical examination vs ultrasound.

Janow GL, Panghaal V, Trinh A, Badger D, Levin TL, Ilowite NT.

J Rheumatol. 2011 Dec;38(12):2671-4. doi: 10.3899/jrheum.110360. Epub 2011 Sep 15.

PMID:
21921099
40.

Chronic leg ulceration as the presenting feature of diffuse systemic sclerosis in childhood.

Wahezi DM, Ilowite NT, Kenney-Riley KM, Belamarich PF.

J Pediatr. 2011 Oct;159(4):698. doi: 10.1016/j.jpeds.2011.05.046. Epub 2011 Jul 23. No abstract available.

PMID:
21784448
41.

2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.

Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N.

Arthritis Care Res (Hoboken). 2011 Apr;63(4):465-82. doi: 10.1002/acr.20460. Review. No abstract available.

42.

Wasabi nose: an underreported complication of cyclophosphamide infusions.

Janow GL, Ilowite NT, Wahezi DM.

Clin Rheumatol. 2011 Jul;30(7):1003-5. doi: 10.1007/s10067-011-1728-z. Epub 2011 Mar 8. Review.

PMID:
21384255
43.

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.

Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, Cortis E, Pardeo M, Miettunen PM, Janow G, Birmingham J, Eggebeen A, Janssen E, Shulman AI, Son MB, Hong S, Jones K, Ilowite NT, Cron RQ, Higgins GC.

Arthritis Rheum. 2011 Feb;63(2):545-55. doi: 10.1002/art.30128.

44.

Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort.

Ardoin SP, Schanberg LE, Sandborg C, Yow E, Barnhart HX, Mieszkalski Kl, Ilowite NT, von Scheven E, Eberhard A, Levy DM, Kimura Y, Silverman E, Bowyer SL, Punaro L, Singer NG, Sherry DD, McCurdy D, Klein-Gitelman M, Wallace C, Silver R, Wagner-Weiner L, Higgins GC, Brunner HI, Jung LK, Imundo L, Soep JB, Reed AM; APPLE investigators.

Lupus. 2010 Oct;19(11):1315-25. doi: 10.1177/0961203310373937.

45.

Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis.

Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Henrickson M, Ilowite NT, Kimura Y, DeWitt EM, Segerman J, Stein LD, Taylor J, Vehe RK, Giannini EH.

Arthritis Care Res (Hoboken). 2011 Jan;63(1):10-6. doi: 10.1002/acr.20348.

46.

Cranial nerve involvement with juvenile polyarteritis nodosa: clinical manifestations and treatment.

Wahezi DM, Gomes WA, Ilowite NT.

Pediatrics. 2010 Sep;126(3):e719-22. doi: 10.1542/peds.2009-3331. Epub 2010 Aug 23.

PMID:
20732942
47.

Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis.

Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Chon Y, Zhang N, Baumgartner SW.

Arthritis Rheum. 2010 Nov;62(11):3259-64. doi: 10.1002/art.27682.

48.

Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.

Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Singer NG, Chon Y, Lin SL, Baumgartner SW; Pediatric Rheumatology Collaborative Study Group.

Arthritis Rheum. 2009 Sep;60(9):2794-804. doi: 10.1002/art.24777.

49.

Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis.

Barnes MG, Grom AA, Thompson SD, Griffin TA, Pavlidis P, Itert L, Fall N, Sowders DP, Hinze CH, Aronow BJ, Luyrink LK, Srivastava S, Ilowite NT, Gottlieb BS, Olson JC, Sherry DD, Glass DN, Colbert RA.

Arthritis Rheum. 2009 Jul;60(7):2102-12. doi: 10.1002/art.24601.

50.

Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets.

Griffin TA, Barnes MG, Ilowite NT, Olson JC, Sherry DD, Gottlieb BS, Aronow BJ, Pavlidis P, Hinze CH, Thornton S, Thompson SD, Grom AA, Colbert RA, Glass DN.

Arthritis Rheum. 2009 Jul;60(7):2113-23. doi: 10.1002/art.24534.

Supplemental Content

Loading ...
Support Center